nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—CYP2B6—Thiotepa—urinary bladder cancer	0.153	0.264	CbGbCtD
Loperamide—ABCB1—Mitomycin—urinary bladder cancer	0.103	0.179	CbGbCtD
Loperamide—CYP3A4—Thiotepa—urinary bladder cancer	0.047	0.0811	CbGbCtD
Loperamide—CYP2B6—Cisplatin—urinary bladder cancer	0.0422	0.0729	CbGbCtD
Loperamide—CYP2C8—Fluorouracil—urinary bladder cancer	0.0376	0.065	CbGbCtD
Loperamide—CYP2C8—Etoposide—urinary bladder cancer	0.0314	0.0542	CbGbCtD
Loperamide—ABCB1—Gemcitabine—urinary bladder cancer	0.0298	0.0514	CbGbCtD
Loperamide—CYP2B6—Doxorubicin—urinary bladder cancer	0.0283	0.0488	CbGbCtD
Loperamide—POMC—urine—urinary bladder cancer	0.0231	0.22	CbGeAlD
Loperamide—ABCB1—Cisplatin—urinary bladder cancer	0.0216	0.0374	CbGbCtD
Loperamide—ABCB1—Etoposide—urinary bladder cancer	0.0212	0.0367	CbGbCtD
Loperamide—ABCB1—Doxorubicin—urinary bladder cancer	0.0145	0.025	CbGbCtD
Loperamide—ABCB1—Methotrexate—urinary bladder cancer	0.014	0.0243	CbGbCtD
Loperamide—CYP2D6—Doxorubicin—urinary bladder cancer	0.0137	0.0236	CbGbCtD
Loperamide—CYP3A4—Etoposide—urinary bladder cancer	0.0127	0.022	CbGbCtD
Loperamide—CYP3A4—Doxorubicin—urinary bladder cancer	0.00868	0.015	CbGbCtD
Loperamide—POMC—renal system—urinary bladder cancer	0.00565	0.0538	CbGeAlD
Loperamide—POMC—female reproductive system—urinary bladder cancer	0.00453	0.0431	CbGeAlD
Loperamide—OPRK1—prostate gland—urinary bladder cancer	0.00439	0.0417	CbGeAlD
Loperamide—POMC—vagina—urinary bladder cancer	0.00409	0.0389	CbGeAlD
Loperamide—CYP3A4—urine—urinary bladder cancer	0.00354	0.0337	CbGeAlD
Loperamide—CYP2D6—urine—urinary bladder cancer	0.00348	0.0331	CbGeAlD
Loperamide—OPRD1—renal system—urinary bladder cancer	0.00312	0.0297	CbGeAlD
Loperamide—CALM3—prostate gland—urinary bladder cancer	0.00288	0.0274	CbGeAlD
Loperamide—CALM3—seminal vesicle—urinary bladder cancer	0.00244	0.0232	CbGeAlD
Loperamide—OPRK1—female reproductive system—urinary bladder cancer	0.00239	0.0228	CbGeAlD
Loperamide—Ileus—Thiotepa—urinary bladder cancer	0.00239	0.0176	CcSEcCtD
Loperamide—CALM2—prostate gland—urinary bladder cancer	0.00226	0.0215	CbGeAlD
Loperamide—CALM1—prostate gland—urinary bladder cancer	0.00225	0.0214	CbGeAlD
Loperamide—Flatulence—Valrubicin—urinary bladder cancer	0.0021	0.0155	CcSEcCtD
Loperamide—CALM3—smooth muscle tissue—urinary bladder cancer	0.00204	0.0194	CbGeAlD
Loperamide—CALM3—urethra—urinary bladder cancer	0.00193	0.0184	CbGeAlD
Loperamide—CALM2—seminal vesicle—urinary bladder cancer	0.00192	0.0182	CbGeAlD
Loperamide—Drowsiness—Mitomycin—urinary bladder cancer	0.00188	0.0138	CcSEcCtD
Loperamide—Discomfort—Valrubicin—urinary bladder cancer	0.0018	0.0132	CcSEcCtD
Loperamide—Bullous eruption—Epirubicin—urinary bladder cancer	0.00172	0.0127	CcSEcCtD
Loperamide—CALM2—epithelium—urinary bladder cancer	0.00166	0.0158	CbGeAlD
Loperamide—CALM1—epithelium—urinary bladder cancer	0.00166	0.0158	CbGeAlD
Loperamide—CALM2—smooth muscle tissue—urinary bladder cancer	0.0016	0.0153	CbGeAlD
Loperamide—CALM1—smooth muscle tissue—urinary bladder cancer	0.0016	0.0152	CbGeAlD
Loperamide—Bullous eruption—Doxorubicin—urinary bladder cancer	0.00159	0.0117	CcSEcCtD
Loperamide—CALM2—renal system—urinary bladder cancer	0.00154	0.0147	CbGeAlD
Loperamide—CALM1—renal system—urinary bladder cancer	0.00154	0.0146	CbGeAlD
Loperamide—CALM2—urethra—urinary bladder cancer	0.00152	0.0144	CbGeAlD
Loperamide—CALM1—urethra—urinary bladder cancer	0.00151	0.0144	CbGeAlD
Loperamide—Gastrointestinal pain—Valrubicin—urinary bladder cancer	0.00142	0.0105	CcSEcCtD
Loperamide—CALM3—vagina—urinary bladder cancer	0.00142	0.0135	CbGeAlD
Loperamide—Abdominal pain—Valrubicin—urinary bladder cancer	0.00138	0.0101	CcSEcCtD
Loperamide—Loss of consciousness—Mitomycin—urinary bladder cancer	0.00129	0.0095	CcSEcCtD
Loperamide—CYP2C8—renal system—urinary bladder cancer	0.00128	0.0122	CbGeAlD
Loperamide—Asthenia—Valrubicin—urinary bladder cancer	0.00125	0.00919	CcSEcCtD
Loperamide—Discomfort—Mitomycin—urinary bladder cancer	0.00124	0.0091	CcSEcCtD
Loperamide—CALM2—female reproductive system—urinary bladder cancer	0.00124	0.0118	CbGeAlD
Loperamide—Pruritus—Valrubicin—urinary bladder cancer	0.00123	0.00906	CcSEcCtD
Loperamide—CALM1—female reproductive system—urinary bladder cancer	0.00123	0.0117	CbGeAlD
Loperamide—Diarrhoea—Valrubicin—urinary bladder cancer	0.00119	0.00876	CcSEcCtD
Loperamide—Urinary retention—Thiotepa—urinary bladder cancer	0.00117	0.00859	CcSEcCtD
Loperamide—Dizziness—Valrubicin—urinary bladder cancer	0.00115	0.00847	CcSEcCtD
Loperamide—CYP2B6—renal system—urinary bladder cancer	0.00115	0.0109	CbGeAlD
Loperamide—CALM2—vagina—urinary bladder cancer	0.00112	0.0106	CbGeAlD
Loperamide—CALM1—vagina—urinary bladder cancer	0.00111	0.0106	CbGeAlD
Loperamide—Vomiting—Valrubicin—urinary bladder cancer	0.00111	0.00814	CcSEcCtD
Loperamide—Rash—Valrubicin—urinary bladder cancer	0.0011	0.00808	CcSEcCtD
Loperamide—Dermatitis—Valrubicin—urinary bladder cancer	0.0011	0.00807	CcSEcCtD
Loperamide—Headache—Valrubicin—urinary bladder cancer	0.00109	0.00802	CcSEcCtD
Loperamide—Dermatitis bullous—Gemcitabine—urinary bladder cancer	0.00108	0.00795	CcSEcCtD
Loperamide—Anaphylactoid reaction—Gemcitabine—urinary bladder cancer	0.00107	0.00785	CcSEcCtD
Loperamide—Somnolence—Mitomycin—urinary bladder cancer	0.00107	0.00785	CcSEcCtD
Loperamide—Dermatitis bullous—Fluorouracil—urinary bladder cancer	0.00106	0.00781	CcSEcCtD
Loperamide—Nausea—Valrubicin—urinary bladder cancer	0.00103	0.00761	CcSEcCtD
Loperamide—Fatigue—Mitomycin—urinary bladder cancer	0.00103	0.00761	CcSEcCtD
Loperamide—CYP2C8—female reproductive system—urinary bladder cancer	0.00102	0.00975	CbGeAlD
Loperamide—Anaphylactoid reaction—Cisplatin—urinary bladder cancer	0.000995	0.00731	CcSEcCtD
Loperamide—Ileus—Epirubicin—urinary bladder cancer	0.000962	0.00708	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Gemcitabine—urinary bladder cancer	0.00093	0.00684	CcSEcCtD
Loperamide—CYP2C8—vagina—urinary bladder cancer	0.000926	0.00881	CbGeAlD
Loperamide—CALM3—lymph node—urinary bladder cancer	0.000921	0.00876	CbGeAlD
Loperamide—CYP2B6—female reproductive system—urinary bladder cancer	0.000919	0.00874	CbGeAlD
Loperamide—Anaphylactoid reaction—Etoposide—urinary bladder cancer	0.000911	0.0067	CcSEcCtD
Loperamide—ABCB1—prostate gland—urinary bladder cancer	0.0009	0.00856	CbGeAlD
Loperamide—Ileus—Doxorubicin—urinary bladder cancer	0.00089	0.00655	CcSEcCtD
Loperamide—CYP3A4—renal system—urinary bladder cancer	0.000866	0.00824	CbGeAlD
Loperamide—Asthenia—Mitomycin—urinary bladder cancer	0.000861	0.00633	CcSEcCtD
Loperamide—CYP2D6—renal system—urinary bladder cancer	0.000853	0.00811	CbGeAlD
Loperamide—Urinary tract disorder—Thiotepa—urinary bladder cancer	0.000839	0.00617	CcSEcCtD
Loperamide—Urethral disorder—Thiotepa—urinary bladder cancer	0.000833	0.00612	CcSEcCtD
Loperamide—CYP2B6—vagina—urinary bladder cancer	0.000831	0.00791	CbGeAlD
Loperamide—Diarrhoea—Mitomycin—urinary bladder cancer	0.000821	0.00604	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Etoposide—urinary bladder cancer	0.000794	0.00584	CcSEcCtD
Loperamide—Dizziness—Mitomycin—urinary bladder cancer	0.000794	0.00584	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Gemcitabine—urinary bladder cancer	0.000789	0.0058	CcSEcCtD
Loperamide—Immune system disorder—Thiotepa—urinary bladder cancer	0.000767	0.00564	CcSEcCtD
Loperamide—Vomiting—Mitomycin—urinary bladder cancer	0.000763	0.00561	CcSEcCtD
Loperamide—ABCB1—seminal vesicle—urinary bladder cancer	0.000761	0.00724	CbGeAlD
Loperamide—Rash—Mitomycin—urinary bladder cancer	0.000757	0.00556	CcSEcCtD
Loperamide—Dermatitis—Mitomycin—urinary bladder cancer	0.000756	0.00556	CcSEcCtD
Loperamide—Headache—Mitomycin—urinary bladder cancer	0.000752	0.00553	CcSEcCtD
Loperamide—CALM2—lymph node—urinary bladder cancer	0.000723	0.00688	CbGeAlD
Loperamide—CALM1—lymph node—urinary bladder cancer	0.00072	0.00685	CbGeAlD
Loperamide—Nausea—Mitomycin—urinary bladder cancer	0.000713	0.00524	CcSEcCtD
Loperamide—Urinary tract disorder—Gemcitabine—urinary bladder cancer	0.000706	0.00519	CcSEcCtD
Loperamide—Depressed level of consciousness—Methotrexate—urinary bladder cancer	0.000703	0.00517	CcSEcCtD
Loperamide—Urethral disorder—Gemcitabine—urinary bladder cancer	0.0007	0.00515	CcSEcCtD
Loperamide—CYP3A4—female reproductive system—urinary bladder cancer	0.000694	0.0066	CbGeAlD
Loperamide—CYP2D6—female reproductive system—urinary bladder cancer	0.000683	0.0065	CbGeAlD
Loperamide—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.000676	0.00497	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Etoposide—urinary bladder cancer	0.000674	0.00496	CcSEcCtD
Loperamide—ABCB1—epithelium—urinary bladder cancer	0.000661	0.00629	CbGeAlD
Loperamide—Urinary tract disorder—Cisplatin—urinary bladder cancer	0.000658	0.00484	CcSEcCtD
Loperamide—Urethral disorder—Cisplatin—urinary bladder cancer	0.000653	0.0048	CcSEcCtD
Loperamide—Immune system disorder—Gemcitabine—urinary bladder cancer	0.000645	0.00475	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000625	0.0046	CcSEcCtD
Loperamide—ABCB1—renal system—urinary bladder cancer	0.000613	0.00583	CbGeAlD
Loperamide—Urinary tract disorder—Etoposide—urinary bladder cancer	0.000603	0.00443	CcSEcCtD
Loperamide—ABCB1—urethra—urinary bladder cancer	0.000602	0.00573	CbGeAlD
Loperamide—Immune system disorder—Cisplatin—urinary bladder cancer	0.000602	0.00442	CcSEcCtD
Loperamide—Urethral disorder—Etoposide—urinary bladder cancer	0.000598	0.0044	CcSEcCtD
Loperamide—Toremifene—ESR1—urinary bladder cancer	0.000595	0.488	CrCbGaD
Loperamide—Nervous system disorder—Thiotepa—urinary bladder cancer	0.000592	0.00435	CcSEcCtD
Loperamide—Skin disorder—Thiotepa—urinary bladder cancer	0.000586	0.00431	CcSEcCtD
Loperamide—Erythema multiforme—Etoposide—urinary bladder cancer	0.000577	0.00424	CcSEcCtD
Loperamide—Flatulence—Cisplatin—urinary bladder cancer	0.000571	0.0042	CcSEcCtD
Loperamide—Immune system disorder—Etoposide—urinary bladder cancer	0.000551	0.00405	CcSEcCtD
Loperamide—Anaphylactoid reaction—Methotrexate—urinary bladder cancer	0.000546	0.00401	CcSEcCtD
Loperamide—Somnolence—Thiotepa—urinary bladder cancer	0.000537	0.00395	CcSEcCtD
Loperamide—Dyspepsia—Thiotepa—urinary bladder cancer	0.000531	0.00391	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000526	0.00387	CcSEcCtD
Loperamide—Discomfort—Gemcitabine—urinary bladder cancer	0.000523	0.00385	CcSEcCtD
Loperamide—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000521	0.00383	CcSEcCtD
Loperamide—Fatigue—Thiotepa—urinary bladder cancer	0.00052	0.00383	CcSEcCtD
Loperamide—Dermatitis bullous—Epirubicin—urinary bladder cancer	0.000517	0.0038	CcSEcCtD
Loperamide—Constipation—Thiotepa—urinary bladder cancer	0.000516	0.0038	CcSEcCtD
Loperamide—Discomfort—Fluorouracil—urinary bladder cancer	0.000514	0.00378	CcSEcCtD
Loperamide—Anaphylactoid reaction—Epirubicin—urinary bladder cancer	0.000511	0.00376	CcSEcCtD
Loperamide—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000508	0.00373	CcSEcCtD
Loperamide—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000499	0.00367	CcSEcCtD
Loperamide—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000498	0.00366	CcSEcCtD
Loperamide—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000494	0.00363	CcSEcCtD
Loperamide—Skin disorder—Gemcitabine—urinary bladder cancer	0.000493	0.00363	CcSEcCtD
Loperamide—ABCB1—female reproductive system—urinary bladder cancer	0.000491	0.00467	CbGeAlD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00049	0.0036	CcSEcCtD
Loperamide—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00049	0.0036	CcSEcCtD
Loperamide—Discomfort—Cisplatin—urinary bladder cancer	0.000488	0.00359	CcSEcCtD
Loperamide—Urticaria—Thiotepa—urinary bladder cancer	0.000479	0.00353	CcSEcCtD
Loperamide—Dermatitis bullous—Doxorubicin—urinary bladder cancer	0.000479	0.00352	CcSEcCtD
Loperamide—Abdominal pain—Thiotepa—urinary bladder cancer	0.000477	0.00351	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.000476	0.0035	CcSEcCtD
Loperamide—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000473	0.00348	CcSEcCtD
Loperamide—Anaphylactoid reaction—Doxorubicin—urinary bladder cancer	0.000473	0.00348	CcSEcCtD
Loperamide—Loss of consciousness—Etoposide—urinary bladder cancer	0.000467	0.00343	CcSEcCtD
Loperamide—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000464	0.00341	CcSEcCtD
Loperamide—Skin disorder—Cisplatin—urinary bladder cancer	0.00046	0.00338	CcSEcCtD
Loperamide—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.000452	0.00332	CcSEcCtD
Loperamide—Somnolence—Gemcitabine—urinary bladder cancer	0.000451	0.00332	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000449	0.0033	CcSEcCtD
Loperamide—Discomfort—Etoposide—urinary bladder cancer	0.000447	0.00329	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.000445	0.00327	CcSEcCtD
Loperamide—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000445	0.00327	CcSEcCtD
Loperamide—ABCB1—vagina—urinary bladder cancer	0.000444	0.00423	CbGeAlD
Loperamide—Somnolence—Fluorouracil—urinary bladder cancer	0.000444	0.00326	CcSEcCtD
Loperamide—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000439	0.00323	CcSEcCtD
Loperamide—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000438	0.00322	CcSEcCtD
Loperamide—Fatigue—Gemcitabine—urinary bladder cancer	0.000438	0.00322	CcSEcCtD
Loperamide—Constipation—Gemcitabine—urinary bladder cancer	0.000434	0.00319	CcSEcCtD
Loperamide—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000434	0.00319	CcSEcCtD
Loperamide—Asthenia—Thiotepa—urinary bladder cancer	0.000433	0.00318	CcSEcCtD
Loperamide—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000431	0.00317	CcSEcCtD
Loperamide—Abdominal distension—Epirubicin—urinary bladder cancer	0.00043	0.00316	CcSEcCtD
Loperamide—Pruritus—Thiotepa—urinary bladder cancer	0.000427	0.00314	CcSEcCtD
Loperamide—Skin disorder—Etoposide—urinary bladder cancer	0.000421	0.0031	CcSEcCtD
Loperamide—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.000418	0.00307	CcSEcCtD
Loperamide—Diarrhoea—Thiotepa—urinary bladder cancer	0.000413	0.00304	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.000412	0.00303	CcSEcCtD
Loperamide—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000409	0.003	CcSEcCtD
Loperamide—Drowsiness—Methotrexate—urinary bladder cancer	0.000407	0.00299	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000404	0.00297	CcSEcCtD
Loperamide—Dizziness—Thiotepa—urinary bladder cancer	0.000399	0.00293	CcSEcCtD
Loperamide—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000398	0.00293	CcSEcCtD
Loperamide—Urticaria—Fluorouracil—urinary bladder cancer	0.000397	0.00292	CcSEcCtD
Loperamide—Tamoxifen—ESR2—urinary bladder cancer	0.000386	0.317	CrCbGaD
Loperamide—Somnolence—Etoposide—urinary bladder cancer	0.000385	0.00283	CcSEcCtD
Loperamide—Vomiting—Thiotepa—urinary bladder cancer	0.000384	0.00282	CcSEcCtD
Loperamide—Drowsiness—Epirubicin—urinary bladder cancer	0.000381	0.0028	CcSEcCtD
Loperamide—Rash—Thiotepa—urinary bladder cancer	0.000381	0.0028	CcSEcCtD
Loperamide—Dermatitis—Thiotepa—urinary bladder cancer	0.00038	0.0028	CcSEcCtD
Loperamide—Headache—Thiotepa—urinary bladder cancer	0.000378	0.00278	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000378	0.00278	CcSEcCtD
Loperamide—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000374	0.00275	CcSEcCtD
Loperamide—Fatigue—Etoposide—urinary bladder cancer	0.000374	0.00275	CcSEcCtD
Loperamide—Constipation—Etoposide—urinary bladder cancer	0.000371	0.00273	CcSEcCtD
Loperamide—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000368	0.0027	CcSEcCtD
Loperamide—Asthenia—Gemcitabine—urinary bladder cancer	0.000364	0.00268	CcSEcCtD
Loperamide—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000361	0.00265	CcSEcCtD
Loperamide—Pruritus—Gemcitabine—urinary bladder cancer	0.000359	0.00264	CcSEcCtD
Loperamide—Nausea—Thiotepa—urinary bladder cancer	0.000358	0.00264	CcSEcCtD
Loperamide—Urethral disorder—Methotrexate—urinary bladder cancer	0.000358	0.00263	CcSEcCtD
Loperamide—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000355	0.00261	CcSEcCtD
Loperamide—Pruritus—Fluorouracil—urinary bladder cancer	0.000353	0.0026	CcSEcCtD
Loperamide—Drowsiness—Doxorubicin—urinary bladder cancer	0.000353	0.00259	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.00035	0.00257	CcSEcCtD
Loperamide—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000349	0.00256	CcSEcCtD
Loperamide—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000347	0.00255	CcSEcCtD
Loperamide—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000346	0.00254	CcSEcCtD
Loperamide—Urticaria—Etoposide—urinary bladder cancer	0.000344	0.00253	CcSEcCtD
Loperamide—Abdominal pain—Etoposide—urinary bladder cancer	0.000343	0.00252	CcSEcCtD
Loperamide—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000342	0.00251	CcSEcCtD
Loperamide—Asthenia—Cisplatin—urinary bladder cancer	0.00034	0.0025	CcSEcCtD
Loperamide—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000338	0.00248	CcSEcCtD
Loperamide—Urethral disorder—Epirubicin—urinary bladder cancer	0.000335	0.00247	CcSEcCtD
Loperamide—Immune system disorder—Methotrexate—urinary bladder cancer	0.00033	0.00243	CcSEcCtD
Loperamide—Dizziness—Fluorouracil—urinary bladder cancer	0.00033	0.00243	CcSEcCtD
Loperamide—Diarrhoea—Cisplatin—urinary bladder cancer	0.000324	0.00238	CcSEcCtD
Loperamide—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000323	0.00238	CcSEcCtD
Loperamide—Vomiting—Gemcitabine—urinary bladder cancer	0.000323	0.00237	CcSEcCtD
Loperamide—Rash—Gemcitabine—urinary bladder cancer	0.00032	0.00235	CcSEcCtD
Loperamide—Dermatitis—Gemcitabine—urinary bladder cancer	0.00032	0.00235	CcSEcCtD
Loperamide—Hypersensitivity—Etoposide—urinary bladder cancer	0.000319	0.00235	CcSEcCtD
Loperamide—Headache—Gemcitabine—urinary bladder cancer	0.000318	0.00234	CcSEcCtD
Loperamide—Vomiting—Fluorouracil—urinary bladder cancer	0.000317	0.00233	CcSEcCtD
Loperamide—Rash—Fluorouracil—urinary bladder cancer	0.000315	0.00231	CcSEcCtD
Loperamide—Dermatitis—Fluorouracil—urinary bladder cancer	0.000314	0.00231	CcSEcCtD
Loperamide—Headache—Fluorouracil—urinary bladder cancer	0.000313	0.0023	CcSEcCtD
Loperamide—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000313	0.0023	CcSEcCtD
Loperamide—Asthenia—Etoposide—urinary bladder cancer	0.000311	0.00229	CcSEcCtD
Loperamide—Urethral disorder—Doxorubicin—urinary bladder cancer	0.00031	0.00228	CcSEcCtD
Loperamide—Immune system disorder—Epirubicin—urinary bladder cancer	0.000309	0.00227	CcSEcCtD
Loperamide—Pruritus—Etoposide—urinary bladder cancer	0.000307	0.00226	CcSEcCtD
Loperamide—Nausea—Gemcitabine—urinary bladder cancer	0.000302	0.00222	CcSEcCtD
Loperamide—Vomiting—Cisplatin—urinary bladder cancer	0.000301	0.00221	CcSEcCtD
Loperamide—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000299	0.0022	CcSEcCtD
Loperamide—Rash—Cisplatin—urinary bladder cancer	0.000298	0.00219	CcSEcCtD
Loperamide—Dermatitis—Cisplatin—urinary bladder cancer	0.000298	0.00219	CcSEcCtD
Loperamide—Diarrhoea—Etoposide—urinary bladder cancer	0.000297	0.00218	CcSEcCtD
Loperamide—Nausea—Fluorouracil—urinary bladder cancer	0.000297	0.00218	CcSEcCtD
Loperamide—Flatulence—Epirubicin—urinary bladder cancer	0.000293	0.00216	CcSEcCtD
Loperamide—ABCB1—lymph node—urinary bladder cancer	0.000287	0.00273	CbGeAlD
Loperamide—Dizziness—Etoposide—urinary bladder cancer	0.000287	0.00211	CcSEcCtD
Loperamide—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000286	0.0021	CcSEcCtD
Loperamide—Nausea—Cisplatin—urinary bladder cancer	0.000281	0.00207	CcSEcCtD
Loperamide—Vomiting—Etoposide—urinary bladder cancer	0.000276	0.00203	CcSEcCtD
Loperamide—Rash—Etoposide—urinary bladder cancer	0.000273	0.00201	CcSEcCtD
Loperamide—Dermatitis—Etoposide—urinary bladder cancer	0.000273	0.00201	CcSEcCtD
Loperamide—Headache—Etoposide—urinary bladder cancer	0.000272	0.002	CcSEcCtD
Loperamide—Flatulence—Doxorubicin—urinary bladder cancer	0.000271	0.002	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000269	0.00198	CcSEcCtD
Loperamide—Discomfort—Methotrexate—urinary bladder cancer	0.000268	0.00197	CcSEcCtD
Loperamide—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000262	0.00192	CcSEcCtD
Loperamide—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.00026	0.00191	CcSEcCtD
Loperamide—Nausea—Etoposide—urinary bladder cancer	0.000258	0.00189	CcSEcCtD
Loperamide—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000255	0.00187	CcSEcCtD
Loperamide—Skin disorder—Methotrexate—urinary bladder cancer	0.000252	0.00185	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000252	0.00185	CcSEcCtD
Loperamide—Discomfort—Epirubicin—urinary bladder cancer	0.00025	0.00184	CcSEcCtD
Loperamide—Dry mouth—Epirubicin—urinary bladder cancer	0.000248	0.00182	CcSEcCtD
Loperamide—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000243	0.00179	CcSEcCtD
Loperamide—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000242	0.00178	CcSEcCtD
Loperamide—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000238	0.00175	CcSEcCtD
Loperamide—Tamoxifen—ESR1—urinary bladder cancer	0.000238	0.195	CrCbGaD
Loperamide—Skin disorder—Epirubicin—urinary bladder cancer	0.000236	0.00174	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000233	0.00171	CcSEcCtD
Loperamide—Discomfort—Doxorubicin—urinary bladder cancer	0.000232	0.0017	CcSEcCtD
Loperamide—Somnolence—Methotrexate—urinary bladder cancer	0.000231	0.0017	CcSEcCtD
Loperamide—Dry mouth—Doxorubicin—urinary bladder cancer	0.000229	0.00169	CcSEcCtD
Loperamide—Dyspepsia—Methotrexate—urinary bladder cancer	0.000229	0.00168	CcSEcCtD
Loperamide—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000225	0.00165	CcSEcCtD
Loperamide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000224	0.00165	CcSEcCtD
Loperamide—Fatigue—Methotrexate—urinary bladder cancer	0.000224	0.00165	CcSEcCtD
Loperamide—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000221	0.00162	CcSEcCtD
Loperamide—Skin disorder—Doxorubicin—urinary bladder cancer	0.000218	0.00161	CcSEcCtD
Loperamide—Somnolence—Epirubicin—urinary bladder cancer	0.000216	0.00159	CcSEcCtD
Loperamide—Dyspepsia—Epirubicin—urinary bladder cancer	0.000214	0.00157	CcSEcCtD
Loperamide—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000212	0.00156	CcSEcCtD
Loperamide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00021	0.00154	CcSEcCtD
Loperamide—Fatigue—Epirubicin—urinary bladder cancer	0.00021	0.00154	CcSEcCtD
Loperamide—Constipation—Epirubicin—urinary bladder cancer	0.000208	0.00153	CcSEcCtD
Loperamide—Urticaria—Methotrexate—urinary bladder cancer	0.000206	0.00152	CcSEcCtD
Loperamide—Abdominal pain—Methotrexate—urinary bladder cancer	0.000205	0.00151	CcSEcCtD
Loperamide—Somnolence—Doxorubicin—urinary bladder cancer	0.0002	0.00147	CcSEcCtD
Loperamide—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000199	0.00146	CcSEcCtD
Loperamide—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000198	0.00146	CcSEcCtD
Loperamide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000194	0.00143	CcSEcCtD
Loperamide—Fatigue—Doxorubicin—urinary bladder cancer	0.000194	0.00143	CcSEcCtD
Loperamide—Urticaria—Epirubicin—urinary bladder cancer	0.000193	0.00142	CcSEcCtD
Loperamide—Constipation—Doxorubicin—urinary bladder cancer	0.000192	0.00141	CcSEcCtD
Loperamide—Abdominal pain—Epirubicin—urinary bladder cancer	0.000192	0.00141	CcSEcCtD
Loperamide—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000191	0.00141	CcSEcCtD
Loperamide—Asthenia—Methotrexate—urinary bladder cancer	0.000186	0.00137	CcSEcCtD
Loperamide—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000184	0.00135	CcSEcCtD
Loperamide—Pruritus—Methotrexate—urinary bladder cancer	0.000184	0.00135	CcSEcCtD
Loperamide—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000179	0.00132	CcSEcCtD
Loperamide—Urticaria—Doxorubicin—urinary bladder cancer	0.000179	0.00131	CcSEcCtD
Loperamide—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000178	0.00131	CcSEcCtD
Loperamide—Diarrhoea—Methotrexate—urinary bladder cancer	0.000178	0.00131	CcSEcCtD
Loperamide—Asthenia—Epirubicin—urinary bladder cancer	0.000174	0.00128	CcSEcCtD
Loperamide—Pruritus—Epirubicin—urinary bladder cancer	0.000172	0.00126	CcSEcCtD
Loperamide—Dizziness—Methotrexate—urinary bladder cancer	0.000172	0.00126	CcSEcCtD
Loperamide—Diarrhoea—Epirubicin—urinary bladder cancer	0.000166	0.00122	CcSEcCtD
Loperamide—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000166	0.00122	CcSEcCtD
Loperamide—Vomiting—Methotrexate—urinary bladder cancer	0.000165	0.00121	CcSEcCtD
Loperamide—Rash—Methotrexate—urinary bladder cancer	0.000164	0.0012	CcSEcCtD
Loperamide—Dermatitis—Methotrexate—urinary bladder cancer	0.000164	0.0012	CcSEcCtD
Loperamide—Headache—Methotrexate—urinary bladder cancer	0.000163	0.0012	CcSEcCtD
Loperamide—Asthenia—Doxorubicin—urinary bladder cancer	0.000161	0.00119	CcSEcCtD
Loperamide—Dizziness—Epirubicin—urinary bladder cancer	0.000161	0.00118	CcSEcCtD
Loperamide—Pruritus—Doxorubicin—urinary bladder cancer	0.000159	0.00117	CcSEcCtD
Loperamide—Vomiting—Epirubicin—urinary bladder cancer	0.000155	0.00114	CcSEcCtD
Loperamide—Nausea—Methotrexate—urinary bladder cancer	0.000154	0.00113	CcSEcCtD
Loperamide—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000154	0.00113	CcSEcCtD
Loperamide—Rash—Epirubicin—urinary bladder cancer	0.000153	0.00113	CcSEcCtD
Loperamide—Dermatitis—Epirubicin—urinary bladder cancer	0.000153	0.00113	CcSEcCtD
Loperamide—Headache—Epirubicin—urinary bladder cancer	0.000152	0.00112	CcSEcCtD
Loperamide—Dizziness—Doxorubicin—urinary bladder cancer	0.000149	0.00109	CcSEcCtD
Loperamide—Nausea—Epirubicin—urinary bladder cancer	0.000144	0.00106	CcSEcCtD
Loperamide—Vomiting—Doxorubicin—urinary bladder cancer	0.000143	0.00105	CcSEcCtD
Loperamide—Rash—Doxorubicin—urinary bladder cancer	0.000142	0.00104	CcSEcCtD
Loperamide—Dermatitis—Doxorubicin—urinary bladder cancer	0.000142	0.00104	CcSEcCtD
Loperamide—Headache—Doxorubicin—urinary bladder cancer	0.000141	0.00104	CcSEcCtD
Loperamide—Nausea—Doxorubicin—urinary bladder cancer	0.000134	0.000982	CcSEcCtD
Loperamide—CALM2—Innate Immune System—KRAS—urinary bladder cancer	1.38e-05	7.72e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—KRAS—urinary bladder cancer	1.38e-05	7.72e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NCOR1—urinary bladder cancer	1.38e-05	7.7e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NCOR1—urinary bladder cancer	1.38e-05	7.7e-05	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—KRAS—urinary bladder cancer	1.37e-05	7.66e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—TP53—urinary bladder cancer	1.36e-05	7.62e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—TP53—urinary bladder cancer	1.36e-05	7.62e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—CREBBP—urinary bladder cancer	1.35e-05	7.57e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—CREBBP—urinary bladder cancer	1.35e-05	7.57e-05	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—HRAS—urinary bladder cancer	1.35e-05	7.54e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—MMP9—urinary bladder cancer	1.35e-05	7.53e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.34e-05	7.5e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—PTEN—urinary bladder cancer	1.34e-05	7.48e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—ERBB2—urinary bladder cancer	1.33e-05	7.41e-05	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—KRAS—urinary bladder cancer	1.33e-05	7.41e-05	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—KRAS—urinary bladder cancer	1.33e-05	7.41e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.32e-05	7.4e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—CXCL8—urinary bladder cancer	1.32e-05	7.37e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	1.31e-05	7.32e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.31e-05	7.3e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—HRAS—urinary bladder cancer	1.3e-05	7.29e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—HRAS—urinary bladder cancer	1.3e-05	7.29e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.29e-05	7.22e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.29e-05	7.22e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.29e-05	7.2e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.29e-05	7.2e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—EP300—urinary bladder cancer	1.28e-05	7.13e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—CXCL8—urinary bladder cancer	1.27e-05	7.13e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.27e-05	7.13e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—ERBB2—urinary bladder cancer	1.27e-05	7.1e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—MYC—urinary bladder cancer	1.27e-05	7.09e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—RHOA—urinary bladder cancer	1.27e-05	7.08e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—IL2—urinary bladder cancer	1.26e-05	7.04e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CXCL8—urinary bladder cancer	1.26e-05	7.03e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TERT—urinary bladder cancer	1.25e-05	7.02e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PPARG—urinary bladder cancer	1.25e-05	7.01e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—HRAS—urinary bladder cancer	1.25e-05	6.99e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.25e-05	6.98e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—SRC—urinary bladder cancer	1.24e-05	6.94e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—EGFR—urinary bladder cancer	1.24e-05	6.94e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.24e-05	6.91e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.23e-05	6.88e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—ERBB2—urinary bladder cancer	1.23e-05	6.87e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—ERBB2—urinary bladder cancer	1.23e-05	6.87e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—RHOA—urinary bladder cancer	1.23e-05	6.85e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—RHOA—urinary bladder cancer	1.23e-05	6.85e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PPARG—urinary bladder cancer	1.22e-05	6.82e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—IL2—urinary bladder cancer	1.22e-05	6.81e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—IL2—urinary bladder cancer	1.22e-05	6.81e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.22e-05	6.8e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.22e-05	6.8e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TERT—urinary bladder cancer	1.21e-05	6.79e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TERT—urinary bladder cancer	1.21e-05	6.79e-05	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—HRAS—urinary bladder cancer	1.21e-05	6.78e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.21e-05	6.78e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	1.2e-05	6.73e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IL2—urinary bladder cancer	1.2e-05	6.72e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PPARG—urinary bladder cancer	1.18e-05	6.6e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PPARG—urinary bladder cancer	1.18e-05	6.6e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—HRAS—urinary bladder cancer	1.17e-05	6.56e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—HRAS—urinary bladder cancer	1.17e-05	6.56e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—CREBBP—urinary bladder cancer	1.17e-05	6.55e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—ERBB2—urinary bladder cancer	1.17e-05	6.55e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—KRAS—urinary bladder cancer	1.17e-05	6.55e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CCND1—urinary bladder cancer	1.17e-05	6.55e-05	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—HRAS—urinary bladder cancer	1.17e-05	6.51e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.16e-05	6.51e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—FGFR3—urinary bladder cancer	1.15e-05	6.44e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL2—urinary bladder cancer	1.15e-05	6.43e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—PTGS2—urinary bladder cancer	1.15e-05	6.41e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.14e-05	6.39e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.14e-05	6.38e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MMP9—urinary bladder cancer	1.14e-05	6.36e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—CREBBP—urinary bladder cancer	1.13e-05	6.34e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—CREBBP—urinary bladder cancer	1.13e-05	6.34e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—ERBB2—urinary bladder cancer	1.13e-05	6.34e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—ERBB2—urinary bladder cancer	1.13e-05	6.34e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.13e-05	6.34e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—PTEN—urinary bladder cancer	1.13e-05	6.32e-05	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—HRAS—urinary bladder cancer	1.13e-05	6.3e-05	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—HRAS—urinary bladder cancer	1.13e-05	6.3e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—ESR1—urinary bladder cancer	1.12e-05	6.25e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—FGFR3—urinary bladder cancer	1.11e-05	6.23e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—FGFR3—urinary bladder cancer	1.11e-05	6.23e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL2—urinary bladder cancer	1.11e-05	6.22e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL2—urinary bladder cancer	1.11e-05	6.22e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—MYC—urinary bladder cancer	1.11e-05	6.22e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—PTGS2—urinary bladder cancer	1.11e-05	6.2e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—PTGS2—urinary bladder cancer	1.11e-05	6.2e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—EGFR—urinary bladder cancer	1.09e-05	6.08e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—CDKN1A—urinary bladder cancer	1.09e-05	6.07e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—PTEN—urinary bladder cancer	1.08e-05	6.05e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—ESR1—urinary bladder cancer	1.08e-05	6.05e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—ESR1—urinary bladder cancer	1.08e-05	6.05e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—EP300—urinary bladder cancer	1.08e-05	6.03e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.07e-05	6.01e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PPARG—urinary bladder cancer	1.06e-05	5.94e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—CDKN1A—urinary bladder cancer	1.05e-05	5.87e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—CDKN1A—urinary bladder cancer	1.05e-05	5.87e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—SRC—urinary bladder cancer	1.05e-05	5.86e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—PTEN—urinary bladder cancer	1.05e-05	5.86e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—PTEN—urinary bladder cancer	1.05e-05	5.86e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—TP53—urinary bladder cancer	1.04e-05	5.82e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.04e-05	5.8e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—EP300—urinary bladder cancer	1.03e-05	5.77e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—KRAS—urinary bladder cancer	1.03e-05	5.74e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	1.02e-05	5.7e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—SRC—urinary bladder cancer	1e-05	5.61e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—CDKN1A—urinary bladder cancer	1e-05	5.6e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—PTEN—urinary bladder cancer	1e-05	5.59e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—EP300—urinary bladder cancer	9.99e-06	5.58e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—EP300—urinary bladder cancer	9.99e-06	5.58e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—HRAS—urinary bladder cancer	9.96e-06	5.57e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	9.86e-06	5.52e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CREBBP—urinary bladder cancer	9.8e-06	5.48e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—SRC—urinary bladder cancer	9.71e-06	5.43e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—SRC—urinary bladder cancer	9.71e-06	5.43e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—CDKN1A—urinary bladder cancer	9.69e-06	5.42e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—CDKN1A—urinary bladder cancer	9.69e-06	5.42e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IGF1—urinary bladder cancer	9.68e-06	5.41e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—PTEN—urinary bladder cancer	9.67e-06	5.41e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—PTEN—urinary bladder cancer	9.67e-06	5.41e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—EGFR—urinary bladder cancer	9.63e-06	5.39e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PTGS2—urinary bladder cancer	9.6e-06	5.37e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—EP300—urinary bladder cancer	9.53e-06	5.33e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CREBBP—urinary bladder cancer	9.48e-06	5.3e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CREBBP—urinary bladder cancer	9.48e-06	5.3e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MYC—urinary bladder cancer	9.4e-06	5.25e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IGF1—urinary bladder cancer	9.36e-06	5.24e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IGF1—urinary bladder cancer	9.36e-06	5.24e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—EGFR—urinary bladder cancer	9.32e-06	5.21e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—EGFR—urinary bladder cancer	9.32e-06	5.21e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PTGS2—urinary bladder cancer	9.29e-06	5.19e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PTGS2—urinary bladder cancer	9.29e-06	5.19e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—SRC—urinary bladder cancer	9.27e-06	5.18e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PPARG—urinary bladder cancer	9.25e-06	5.17e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—EP300—urinary bladder cancer	9.22e-06	5.16e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—EP300—urinary bladder cancer	9.22e-06	5.16e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—EGFR—urinary bladder cancer	9.19e-06	5.14e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TP53—urinary bladder cancer	9.13e-06	5.11e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—KRAS—urinary bladder cancer	9.1e-06	5.09e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—SRC—urinary bladder cancer	8.97e-06	5.01e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—SRC—urinary bladder cancer	8.97e-06	5.01e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—CREBBP—urinary bladder cancer	8.88e-06	4.97e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—RHOA—urinary bladder cancer	8.87e-06	4.96e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—KRAS—urinary bladder cancer	8.8e-06	4.92e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—KRAS—urinary bladder cancer	8.8e-06	4.92e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—EGFR—urinary bladder cancer	8.8e-06	4.92e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—HRAS—urinary bladder cancer	8.73e-06	4.88e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PPARG—urinary bladder cancer	8.72e-06	4.87e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—KRAS—urinary bladder cancer	8.68e-06	4.86e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	8.65e-06	4.84e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PTEN—urinary bladder cancer	8.6e-06	4.81e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—RHOA—urinary bladder cancer	8.58e-06	4.8e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—RHOA—urinary bladder cancer	8.58e-06	4.8e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—EGFR—urinary bladder cancer	8.51e-06	4.76e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—EGFR—urinary bladder cancer	8.51e-06	4.76e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	8.37e-06	4.68e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PTEN—urinary bladder cancer	8.37e-06	4.68e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	8.35e-06	4.67e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—KRAS—urinary bladder cancer	8.31e-06	4.65e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—MYC—urinary bladder cancer	8.31e-06	4.64e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—ERBB2—urinary bladder cancer	8.21e-06	4.59e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—EP300—urinary bladder cancer	8.2e-06	4.59e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—EGFR—urinary bladder cancer	8.13e-06	4.54e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PTEN—urinary bladder cancer	8.1e-06	4.53e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PTEN—urinary bladder cancer	8.1e-06	4.53e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—TYMS—urinary bladder cancer	8.04e-06	4.5e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—KRAS—urinary bladder cancer	8.04e-06	4.5e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—KRAS—urinary bladder cancer	8.04e-06	4.5e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—MYC—urinary bladder cancer	8.04e-06	4.49e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—MYC—urinary bladder cancer	8.04e-06	4.49e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—EP300—urinary bladder cancer	7.98e-06	4.46e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	7.95e-06	4.45e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	7.95e-06	4.45e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—ERBB2—urinary bladder cancer	7.94e-06	4.44e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—ERBB2—urinary bladder cancer	7.94e-06	4.44e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—EGFR—urinary bladder cancer	7.86e-06	4.39e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—EGFR—urinary bladder cancer	7.86e-06	4.39e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CXCL8—urinary bladder cancer	7.79e-06	4.35e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—HRAS—urinary bladder cancer	7.73e-06	4.32e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—EP300—urinary bladder cancer	7.72e-06	4.32e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—EP300—urinary bladder cancer	7.72e-06	4.32e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TP53—urinary bladder cancer	7.72e-06	4.32e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—KRAS—urinary bladder cancer	7.68e-06	4.29e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GPX1—urinary bladder cancer	7.61e-06	4.26e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CXCL8—urinary bladder cancer	7.53e-06	4.21e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CXCL8—urinary bladder cancer	7.53e-06	4.21e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—HRAS—urinary bladder cancer	7.48e-06	4.18e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—HRAS—urinary bladder cancer	7.48e-06	4.18e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	7.48e-06	4.18e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IL2—urinary bladder cancer	7.44e-06	4.16e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—KRAS—urinary bladder cancer	7.43e-06	4.15e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—KRAS—urinary bladder cancer	7.43e-06	4.15e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—HRAS—urinary bladder cancer	7.38e-06	4.13e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PTEN—urinary bladder cancer	7.28e-06	4.07e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PTGS2—urinary bladder cancer	7.28e-06	4.07e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CCND1—urinary bladder cancer	7.25e-06	4.06e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL2—urinary bladder cancer	7.2e-06	4.02e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL2—urinary bladder cancer	7.2e-06	4.02e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—HRAS—urinary bladder cancer	7.07e-06	3.95e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MMP9—urinary bladder cancer	7.04e-06	3.94e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	7.03e-06	3.93e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CDKN1A—urinary bladder cancer	7.02e-06	3.92e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCND1—urinary bladder cancer	7.02e-06	3.92e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCND1—urinary bladder cancer	7.02e-06	3.92e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PTEN—urinary bladder cancer	7e-06	3.91e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—EP300—urinary bladder cancer	6.95e-06	3.88e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	6.86e-06	3.83e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—HRAS—urinary bladder cancer	6.84e-06	3.82e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—HRAS—urinary bladder cancer	6.84e-06	3.82e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MMP9—urinary bladder cancer	6.81e-06	3.81e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MMP9—urinary bladder cancer	6.81e-06	3.81e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CDKN1A—urinary bladder cancer	6.79e-06	3.79e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CDKN1A—urinary bladder cancer	6.79e-06	3.79e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PTEN—urinary bladder cancer	6.77e-06	3.79e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PTEN—urinary bladder cancer	6.77e-06	3.79e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—EP300—urinary bladder cancer	6.68e-06	3.73e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—HRAS—urinary bladder cancer	6.52e-06	3.65e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—SRC—urinary bladder cancer	6.49e-06	3.63e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—EP300—urinary bladder cancer	6.46e-06	3.61e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—EP300—urinary bladder cancer	6.46e-06	3.61e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PTEN—urinary bladder cancer	6.34e-06	3.55e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—HRAS—urinary bladder cancer	6.31e-06	3.53e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—HRAS—urinary bladder cancer	6.31e-06	3.53e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—SRC—urinary bladder cancer	6.28e-06	3.51e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—SRC—urinary bladder cancer	6.28e-06	3.51e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—EP300—urinary bladder cancer	6.05e-06	3.38e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PTEN—urinary bladder cancer	5.98e-06	3.34e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MYC—urinary bladder cancer	5.82e-06	3.25e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—EP300—urinary bladder cancer	5.7e-06	3.19e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PPARG—urinary bladder cancer	5.7e-06	3.19e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—EGFR—urinary bladder cancer	5.69e-06	3.18e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MYC—urinary bladder cancer	5.63e-06	3.15e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MYC—urinary bladder cancer	5.63e-06	3.15e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—EGFR—urinary bladder cancer	5.5e-06	3.08e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—EGFR—urinary bladder cancer	5.5e-06	3.08e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	5.47e-06	3.06e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—KRAS—urinary bladder cancer	5.38e-06	3.01e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—KRAS—urinary bladder cancer	5.2e-06	2.91e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—KRAS—urinary bladder cancer	5.2e-06	2.91e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TP53—urinary bladder cancer	4.78e-06	2.67e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TP53—urinary bladder cancer	4.62e-06	2.58e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TP53—urinary bladder cancer	4.62e-06	2.58e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—HRAS—urinary bladder cancer	4.57e-06	2.55e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	4.48e-06	2.51e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—HRAS—urinary bladder cancer	4.42e-06	2.47e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—HRAS—urinary bladder cancer	4.42e-06	2.47e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.91e-06	2.19e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.73e-06	2.08e-05	CbGpPWpGaD
